Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
Akeso shares take a hit despite surging sales of cancer drugs
The maker of oncology drugs posted higher half-year revenues but a widening net loss and share sales by its founders have dented investor confidence Key Takeaways: Drug sales rose 49%…
Anew Health taps investor ‘Qi’ with Nasdaq listing plan
The Hong Kong-based provider of pain relief services using traditional Chinese principles aims to raise about $7.2 million through its U.S. listing, valuing it at up to $200 million Key…
Precision cancer drugs show promise for Kelun-Biotech
The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
Baiyunshan serves up high dividend in lieu of vanilla results
Profits from the company’s Great Health segment rose 14% in the first half of 2025, primarily driven by strong results for its popular Wanglaoji herbal tea Key Takeaways: Baiyunshan’s revenue…
Investors pile into CANbridge stock but can the rally last?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies…
XtalPi scores landmark deal for AI drug discovery
The biotech has partnered with U.S. firm DoveTree in a collaboration worth up to $5.99 billion, adding to a slew of major deals for Chinese research firms this year Key…
